SCHEMBL2263953

SCHEMBL2263953

O=C1Nc2ccc(N3CCOCC3)cc2Nc2nnc(Cl)cc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAA1 Q13131 4/20 0.57
PLK4 O00444 3/20 0.57
AURKA O14965 3/20 0.57
CHEK2 O96017 3/20 0.57
CDK1 P06493 3/20 0.57
CDK2 P24941 3/20 0.57
FLT4 P35916 3/20 0.57
KDR P35968 3/20 0.57
CSNK1D P48730 3/20 0.57
GSK3A P49840 3/20 0.57
GSK3B P49841 3/20 0.57
CDK5 Q00535 3/20 0.57
AURKB Q96GD4 3/20 0.57
SGK2 Q9HBY8 3/20 0.57
DYRK1A Q13627 2/20 0.57
CAMK1 Q14012 2/20 0.57
MAPK9 P45984 1/20 0.57
CHEK1 O14757 2/20 0.48
FGFR1 P11362 2/20 0.42
FLT1 P17948 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260262 0.90 PLK4 (0.61) PRKAA1PLK4AURKACHEK2CDK1
SCHEMBL2265197 0.90 PLK4 (0.61) PRKAA1PLK4AURKACHEK2CDK1
SCHEMBL2261136 0.88 PLK4 (0.60) PRKAA1PLK4AURKACHEK2CDK1
SCHEMBL2261495 0.88 PLK4 (0.60) PRKAA1PLK4AURKACHEK2CDK1
SCHEMBL2260730 0.87 PLK4 (0.59) PRKAA1PLK4AURKACHEK2CDK1
SCHEMBL4857624 0.78 CHEK1 (0.60) AURKACHEK2CDK2GSK3BAURKB
SCHEMBL2260312 0.74 GSK3B (1.00) PRKAA1PLK4AURKACHEK2CDK1
SCHEMBL6827446 0.70 CHEK1 (0.43) CHEK1PDGFRBLRRK2RETKIF11
SCHEMBL2260628 0.70 GSK3B (0.64) PRKAA1PLK4AURKACHEK2CDK1
SCHEMBL7284139 0.69 MAPT (0.50) CHEK1PDGFRBKIF11PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994160-B2 Pyridazine compounds as glycogen synthase kinase 3 inhibitors ABBOTT GMBH & CO. KG (DE) 2011-08-09 US claimed
EP-1902055-A1 PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS Abbott GmbH & Co. KG (DE) 2008-03-26 EP claimed
WO-2007006566-A1 PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS ABBOTT GMBH & CO. KG (DE) 2007-01-18 WO claimed
US-7994160-B2 Pyridazine compounds as glycogen synthase kinase 3 inhibitors ABBOTT GMBH & CO. KG (DE) 2011-08-09 US disclosed
US-20090325937-A1 Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors ABBOTT GMBH & CO. KG (DE) 2009-12-31 US disclosed
EP-1902055-A1 PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS Abbott GmbH & Co. KG (DE) 2008-03-26 EP disclosed
WO-2007006566-A1 PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS ABBOTT GMBH & CO. KG (DE) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325937-A1 Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors GSK3B, GSK3A, GYS2 PRKAA1 372/4885PLK4 39/4885AURKA 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.